Positive correlation of serum bio-intact PTH(1-84) but not intact PTH with parathyroid gland size in hemodialysis patients. 2006

Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. inaba-m@med.osaka-cu.ac.jp

To evaluate the usefulness of newly-developed bio-intact parathyroid hormone (Bio-PTH) assay, which measures exclusively intact PTH(1-84) molecule, serum PTH level determined by Bio-PTH assay, in comparison with second-generation intact PTH (I-PTH) assay, was examined for its correlation with parathyroid gland size. Serum PTH was determined in 46 male HD patients, together with bone formation markers bone alkaline phosphatase, intact osteocalcin, N-terminal propeptide of type I collagen, and bone resorption markers deoxypyridinoline, pyridinoline, beta-crossLaps. Maximal diameter of parathyroid gland was determined with ultrasonography as the parathyroid gland size. Serum Ca and Pi correlated significantly with parathyroid gland size rationalizing our method to define parathyroid gland size. Serum Bio-PTH was correlated significantly in a positive manner with parathyroid gland size (R = 0.308, P = 0.0474), whereas serum I-PTH did not. Furthermore, parathyroid gland size did not exhibit a significant correlation with any of bone formation markers or bone resorption markers. The lack of correlation between bone markers and parathyroid gland size in HD patients may be explained by the occurrence of refractoriness of bone to PTH. In conclusion, serum Bio-PTH assay could provide a better assay than I-PTH assay to estimate parathyroid function in HD patients, due mainly to its exclusive correlation with parathyroid gland size.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010280 Parathyroid Glands Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body. Gland, Parathyroid,Glands, Parathyroid,Parathyroid Gland
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000469 Alkaline Phosphatase An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
D014463 Ultrasonography The visualization of deep structures of the body by recording the reflections or echoes of ultrasonic pulses directed into the tissues. Use of ultrasound for imaging or diagnostic purposes employs frequencies ranging from 1.6 to 10 megahertz. Echography,Echotomography,Echotomography, Computer,Sonography, Medical,Tomography, Ultrasonic,Ultrasonic Diagnosis,Ultrasonic Imaging,Ultrasonographic Imaging,Computer Echotomography,Diagnosis, Ultrasonic,Diagnostic Ultrasound,Ultrasonic Tomography,Ultrasound Imaging,Diagnoses, Ultrasonic,Diagnostic Ultrasounds,Imaging, Ultrasonic,Imaging, Ultrasonographic,Imaging, Ultrasound,Imagings, Ultrasonographic,Imagings, Ultrasound,Medical Sonography,Ultrasonic Diagnoses,Ultrasonographic Imagings,Ultrasound, Diagnostic,Ultrasounds, Diagnostic

Related Publications

Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
September 2004, Clinical chemistry,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
January 2006, Nephron. Clinical practice,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
December 1993, Bone and mineral,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
February 1998, The Australian and New Zealand journal of surgery,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
July 2005, Clinical nephrology,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
April 2008, Clinical nephrology,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
May 2007, The Journal of surgical research,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
December 1991, The Journal of clinical endocrinology and metabolism,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
July 2017, Journal of nephropathology,
Masaaki Inaba, and Senji Okuno, and Hidenori Chou, and Yasuo Imanishi, and Misako Ueda, and Tomoyuki Yamakawa, and Eiji Ishimura, and Yoshiki Nishizawa
May 2000, Clinical chemistry,
Copied contents to your clipboard!